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ABSTRACT

The prevention of mother-to-child transmission is one of the most powerful tools in
human immunodeficiency virus type 1 (HIV-1) prevention and has huge potential to
improve both maternal and child health. In the absence of any preventative measures,
infants born to and breastfed by their HIV-positive mothers have roughly a one-in-three
chance of acquiring the infection themselves. HIV can be passed on from mother-to-child
during pregnancy, during labor and delivery, and even after during breastfeeding.
Intrapartum and neonatal single-dose nevirapine (sd-NVP) is the foundation of
preventing mother-to-child transmission in lower resource settings where it has been used
alone or as part of combination regimens. Both its simplicity and its long plasma half-life
contribute to the success of sd-NVP based therapy. However, sd-NVP frequently results in
HIV-1 viral resistance in mothers and children who become HIV infected despite
prophylaxis. Sd-NVP leads to the development of non-nucleoside reverse transcriptase
inhibitors (NNRTI) drug resistance, compromising the success of treatment of mother and
child with subsequent antiretroviral combinations. Resistance to NNRTIs is particularly
worrisome in lower resource settings since many subsequent regimens for maternal and
infant antiretroviral therapy include a NNRTI drug.
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AN OVERVIEW OF HIV-AIDS
HIV-1, the human immunodeficiency virus, is a retrovirus that can lead to acquired
immune deficiency syndrome (AIDS). As a retrovirus, HIV stores its genetic information on
single-stranded RNA instead of double-stranded DNA. After reverse transcription from the
RNA template, HIV DNA enters the nuclei of the immune system’s helper T lymphocytes
(CD4+ cells) and is integrated into the cell’s DNA. After infection, HIV then uses CD4+ cells
as hosts and instructs each cell to make copies of the original virus. New virus particles are
assembled and leave the cell to infect other CD4+ cells throughout the body. This entire
process of HIV replication depletes the number of CD4+ cells, causing the immune system to
become suppressed over time (Stine 2010). There is a less common, yet closely related
strain of HIV called HIV-2 and unless otherwise stated, all subsequent mention of HIV is a
reference to HIV-1.
HIV is the greatest health crisis the world faces today. An estimated 33 million
people are living with HIV and an increasing number of women and children are being
claimed by AIDS-related illnesses or death. Mother-to-child transmission (MTCT) is the
most prevalent source of HIV infection in children. In 2000, the World Health Organization
(WHO) issued recommendations on the use of antiretroviral drugs (ARVs) for preventing
MTCT of HIV (WHO 2010). This thesis will discuss drug resistance induced by single-dose
nevirapine (sd-NVP), a short-course ARV regimen used to prevent MTCT, which has been
shown to not fully suppress the virus.

MOTHER-TO-CHILD TRANSMISSION

Figure 1. MTCT is possible during pregnancy, labor and delivery, and throughout breast
feeding at different proportions (Adapted from ICAP 2010).
Of the 1,200 new pediatric infections occurring daily, more than 90% are estimated
to be attributed to mother-to-child transmission (MTCT) (UNAIDS 2009). MTCT occurs
when an HIV-infected woman passes the virus to her baby. As depicted in Figure 1, this can
happen during pregnancy, labor and delivery, or while breastfeeding. Not all infants born
to women living with HIV will acquire HIV infection. Without any preventative measures,
approximately 25-45% of children will acquire HIV from their untreated mother. The
proportion of children who acquire infection varies by the timing of exposure. There is a
disproportionately high percentage of infections, 35-40%, occurring during labor and
delivery compared with pregnancy (Abrams 2010).

During pregnancy, a woman can

transmit the virus to her fetus in utero as the virus crosses over from the mother into the
fetal bloodstream (Garcia et al. 1999 “Methods”). Although, it is more likely for newborns
to acquire HIV during delivery by ingesting blood or other infected maternal fluids (Kuhn et
al. 1994). If breastfed, the newborn may become infected from breast milk. The likelihood
of infection during breastfeeding depends on the duration of breastfeeding and if the baby
is exclusively fed breast milk or if there is mixed feeding (Abrams 2010). With cesarean
2

sections and the use of antiretroviral drugs, the risk of MTCT can be greatly reduced (WHO
2010).

ANTI-HIV THERAPY
Although there is no cure for HIV, there are drugs called antiretrovirals (ARVs) that
suppress the reproduction of the virus dramatically and help maintain the immune system.
At present there are six different classes of antiretroviral HIV-drugs available.
1. Fusion inhibitors (FIs). FIs are also known as entry inhibitors and work outside the cell
to prevent the first stage of HIV replication. They prevent HIV from entering the CD4+
cell by blocking fusion of HIV’s outer membrane with the CD4+ cell membrane (Levy
2007).
2. Non-nucleoside

reverse

transcriptase

inhibitors

(NNRTIs).

NNRTIs

bind

noncompetitively to reverse transcriptase, which HIV uses to replicate, and inhibit the
enzyme. This stops HIV from reproducing by preventing the conversion of RNA to DNA
(Stine 2010).
3. Nucleoside reverse transcriptase inhibitors (NRTIs). NRTIs are sometimes referred to as
“nukes” and like NNRTIs, interfere with the function of reverse transcriptase. NRTIs act
as false substrates for reverse transcriptase, causing chain termination. This causes
incomplete DNA synthesis and prevents HIV replication (Stine 2010).
4. Integrase inhibitors (IIs). IIs are a new drug class that blocks integrase, an enzyme that
integrates HIV DNA into the nucleus of CD4+ cells (Stine 2010). The first II, raltegravir,
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was approved by the U.S. Food and Drug Administration (FDA) in 2007 and can be
administered to patients with NNRTI resistance (Hammer et al. 2008).
5. Protease inhibitors (PIs). PIs work at the last stage of HIV’s replication cycle by targeting
the HIV-1 protease enzyme which the virus uses to complete replication. By binding to
HIV-1 protease, PIs prevent mature, infectious HIV from being successfully assembled
and released from the infected CD4+ cell (Levy 2007).
6. CCR5 receptor antagonists. This is a new drug class that targets the CCR5 receptor, a
CD4+ co-receptor which is involved in the HIV entry process. HIV binds to CCR5 receptor
antagonists, blocking HIV from binding to CCR5 receptors on the cell and blocking entry
of HIV (Stine 2010).
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Figure 2. More than two million children estimated to be living with HIV globally 1990-2008
(Adapted from UNAIDS 2009).

Recent statistics provided by the Joint United Nations Programme on HIV/AIDS
(UNAIDS) reveal the problematic and global immensity of MTCT. Of the estimated 33.4
million people living with HIV in 2008 alone, 2.1 million were children under 15 years of age
(Figure 2). Even further, 430,000 of the 2.1 million children were newly infected with HIV in
that year with the majority of them contracting the virus during the perinatal and
breastfeeding period (UNAIDS 2009). Although this is a significant reduction from the
estimated 500,000 in 2001, HIV continues to weigh heavily on child mortality in low
resource countries especially those in sub-Saharan Africa. It is estimated that 85% of HIV
positive (HIV+) children are living in sub-Saharan Africa where more than 90% of pediatric
infections are attributed to MTCT (UNAIDS 2008). In contrast, new HIV infections in
children are becoming increasingly rare in higher resource settings. In 2009, less than 1,000
children were estimated to have become infected in all of North America and Western
Europe (UNAIDS 2010).
5

DISPARITY BETWEEN PREVENTING MOTHER-TO-CHILD TRANSMISSION IN
LOWER AND HIGHER RESOURCE SETTINGS
Although the pediatric HIV epidemic still rages overseas, it has been close to two
decades since antiretroviral prophylaxis was proven effective in reducing MTCT. In 1994,
the landmark study Pediatric AIDS Clinical Trials Group Protocol 076 (PACTG 076)
demonstrated efficacy of the NRTI zidovudine (ZDV) to significantly reduce MTCT of HIV
(Abrams 2010).
409 HIV+ pregnant women naïve to ARVs

Treatment arm:
ZDV 500mg/day weeks 14-34 antepartum
+ ZDV 2mg/kg/hr intrapartum + ZDV
1mg/kg/hr during delivery

Placebo arm:
False drug. Same timelines

Transmission rate:
8.3%

Transmission rate:
25.5%

Figure 3. Summary of the PACTG 076 study design and its results (Adapted from Connor et al. 1994).

As shown in Figure 3, the PACTG 076 study placed 409 HIV+ pregnant women who
were not previously exposed to ARVs in either a ZDV group or a placebo group. The
mothers of the ZDV group were given 100mg of ZDV orally five times a day during weeks 14
to 34 antepartum. During intrapartum they were intravenously administered 2mg/kg body
weight ZDV every hour and 1mg/kg every hour during delivery. Their infant(s) were given
2mg/kg body weight ZDV orally every six hours for the first six weeks of life. Results
revealed an 8.3% rate of HIV-1 transmission in the ZDV group, a large drop in comparison to
the 25.5% transmission rate of the placebo group. ZDV therapy also induced a 67.5%
6

reduction in relative risk of HIV-1 transmission. A regimen based on this ZDV model soon
became standard practice for PMTCT in high resource countries such as the United States
(Connor et al. 1994). However, the complexity and expense of this approach, which entails
both oral and intravenous dosing, made it impractical for use in most lower resource
countries.
Despite the proven effectiveness of perinatal ZDV therapy based on the PACTG 076
study, there still remains a need for less complex and more cost effective regimens that
could be used in both higher resource and lower resource settings. Today, the estimated
MTCT rate is 30% in low resource countries. In stark contrast, MTCT rates are reported at 12% in most high resource settings around the world (Katz et al. 2008). MTCT has virtually
been eliminated in high resource settings as a result of voluntary testing and counseling,
widespread and routine access to ARV prophylaxis directed at suppressive therapy in
pregnant women, safe delivery practices, and the ability and safe use of breast milk
substitutes—all of which will be discussed further on (Townsend 2008). First, it must be
understood why this disparity between low and high resource settings seems to plague
global MTCT prevention strategies.

GLOBAL PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: INADEQUATE
PREVENTION EFFORTS
It is clear that there has not been great success preventing pediatric infections in low
resource, high HIV prevalence settings. Since prevention programs were put in place over a
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decade ago, there has only been an estimated 200,000 averted infections and in 2008, only
70,000 pediatric infections were averted as seen in Figure 4 (UNAIDS 2009).

Figure 4. Estimated number of new pediatric infections with and without ARV prophylaxis, global
level, 1996-2008 (UNAIDS 2009).

Turning to the key elements that guide the global strategy on PMTCT it is easy to see
why this is such a difficult problem in lower resource settings.

ELEMENTS OF SUCCESS: PREVENTING MOTHER-TO-CHILD TRANSMISSION
According to the United Nations, the four main elements of prevention that must be
met are as follows:
1. Prevention of HIV in women of childbearing age.
In 2008, more than one million women were newly infected with HIV with an
especially high risk among those entering reproductive years (UNAIDS 2009). Female
youth are at a disproportionately high risk of acquiring HIV. There is a 3-5 fold higher
prevalence of HIV among young girls in comparison to boys in high prevalence countries.

8

This can be seen in sub-Saharan Africa where 75% of youth living with HIV are females
(WHO 2009).
For women living in high HIV-prevalent settings, the greatest risk of acquiring
infection is through marriage or cohabitation. In a study done in Zambia and Rwanda,
an estimated 55.1-92.7% of heterosexual transmission occurs within a marital or
cohabiting relationship (Dunkle 2008). Most heterosexual HIV transmission for women
takes places within marriage or cohabitation, a time in which most women start thinking
about family. Therefore, counseling and testing for couples should be promoted to
prevent any possible MTCT.
2. Prevention of unwanted pregnancies.
Worldwide, the prevention of unwanted pregnancies has not been met with
success. There is an average of 80 million unintended pregnancies worldwide annually
among women (Abrams 2010). Given this, it is not surprising that there is a very high
unmet need for family planning among HIV-infected women.

In lower resource

countries, more than a quarter of women living with HIV report no desire for their
current pregnancy or the wish to delay their next pregnancy by two years (UNAIDS
2010). In order to produce better outcomes for babies and their mothers and prevent
new pediatric infections, there must be a strengthening of family planning services
along with contraceptive use.
3. Prevention of transmission from an HIV+ woman to her child.
Most efforts for PMTCT depend on identifying HIV+ pregnant women and
providing them with ARV prophylaxis treatment. In 2010, the proportion of pregnant
9

women in low and middle-income countries who received an HIV test reached 26%, up
from 7% in 2005 (ICAP 2010). Although this shows progress, it is still a low figure. The
development of these programs has been overwhelmed by the rapid and successful
expansion of ARV treatment opportunities in low resource settings. However, one must
note the disproportionately smaller number of pregnant women presently receiving
antiretroviral therapy (ART) in comparison to the high number who are eligible for
treatment.

Since PMTCT programs are typically tacked on to already limited

infrastructure for maternal-child health services, there has been a systematic failure to
identify, prioritize, and treat pregnant women eligible for therapeutic ART. This is
estimated to be about 20% of all pregnant women if using a CD4+ count of less than
200cells/μL. These women are at the highest risk for MTCT and for mortality (UNAIDS
2010).
In order to successfully achieve PMTCT, the infant must remain HIV negative
(HIV-). It has been shown that an elective cesarean section reduces MTCT about 50%
independent of ARV therapy (Garcia et al. 1999 “Mode”). This is difficult to achieve in
settings with limited implementation of PMTCT programs. A limited infrastructure
cannot provide a large number of antenatal care visits, institutional deliveries, or
complex medical interventions. And even if there is a program in place, most programs
still rely on short-course, monotherapy ART regimens that are of modest effectiveness
and prone to antiretroviral resistance. Although short-course regimens are a relatively
straightforward method of prevention, they only provide acute, episodic care rather

10

than recognizing the chronic nature and duration of exposure that occurs during
pregnancy and breastfeeding (Abrams 2010).
As stated previously, the risk of MTCT extends throughout breastfeeding. In
settings where breastfeeding is essential for child survival, milk substitutes are generally
not safe or feasible. Therefore, there is still a focus on the unsuccessful infant feeding
methods (Abrams 2010).
4. Providing care and treatment for HIV-infected mothers and their family.
For every mother living with HIV, a family is affected. If the disease kills a mother,
it has the ability to fuel despair among her children and family. It has recently been
found that keeping HIV+ adults in the family healthy reduces the risk of pediatric HIV
and orphanhood. In their work in Uganda, Mermin and colleagues treated HIV+ adults
with ART and cotrimoxazole, a sulfa drug that eliminates bacteria associated with
common infections. They found an 81% reduction in death of uninfected children less
than ten years old within the household as well as a startling 93% reduction in
orphanhood (Mermin et al. 2008).

MATERNAL HEALTH INFLUENCES CHILD HEALTH OUTCOMES
Over the last decade, scientists have identified two factors that have the biggest
impact on transmission: the degree of advancement of maternal infection and ARV
medications (Abrams 2010). It is clear that both these factors have become linked and this
interconnectedness will be discussed in detail later.

11

Women with advanced HIV disease are at the greatest risk for their own disease
progression and for transmission. In 1999, Garcia and colleagues identified the relationship
between the risk of MTCT and the maternal viral load. As seen in Table 1, women with
higher levels of plasma HIV RNA were associated with increasing rates of MTCT
transmission. The risk was 0% among women with less than 1,000copies/mL. The highest
rate of transmission was among women whose plasma HIV RNA levels exceeded
100,000copies/mL with 40.6% of non-breastfeeding babies acquiring HIV (Garcia et al. 1999
“Maternal”). Using the data found in the Garcia et al. study, statistically the mean maternal
HIV-1 RNA viral load of transmission is 30,0000copies/mL and the mean viral load of nontransmitters is 10,000copies/mL.
Table 1. Relationship between the maternal plasma HIV RNA and MTCT rates (Garcia et al. 1999
“Maternal”).

Children born HIV+ to women with advanced HIV disease are more likely to show
high viral loads during the first months of life and are at a higher risk of developing AIDS or
dying (Shearer 1997). Even those born HIV- have a higher risk of death when born to
mothers with advanced HIV. In a study done in Zimbabwe, it was found that uninfected
infants born to infected mothers have at least twice the mortality rate of infants born to
uninfected mothers (Marinda 2007).
12

ANTIRETROVIRAL PROPHYLAXIS
TRANSMISSION OF HIV

IN

REDUCING

MOTHER-TO-CHILD

Antiretroviral drugs (ARVs) reduce perinatal transmission by several mechanisms,
including lowering maternal antepartum viral load and providing the infant with pre- and
post-exposure prophylaxis. A combination of antepartum, intrapartum, and infant ARV
prophylaxis is recommended to prevent MTCT (“Panel on Treatment” 2011).
Lowering maternal viral load. Antenatal ARVs lessen the maternal viral load, which is
particularly important in women with high viral loads. Even among women with HIV RNA
plasma levels less than 1,000copies/mL, ARV drugs have been shown to reduce the risk of
transmission (Ioannidis et al. 2001).
Providing infant with prophylaxis. An infant can become pre-exposed to ARVs when
ARV drugs cross the placental barrier and create systemic drug levels in the fetus. This
mechanism of protection is important during the infant’s passage through the birth canal, a
time in which it is exposed to the virus in the mother’s genital tract. Infant post-exposure
prophylaxis can be achieved by administering ARVs soon after birth. This intervention
provides protection from prior exposure to the mother’s HIV virus that may have occurred
through labor or passage through the birth canal (Garcia et al. 1999 “The Mode”).
The efficacy of antiretroviral drugs in preventing mother-to-child transmission of HIV
is multifactorial and varies with the type of regimen used and the duration over which it is
administered. Combination regimens include different types of antiretroviral drugs and are
more efficacious than monotherapies. Monotherapies, discussed later in detail, are prone
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to antiretroviral resistance in the virus and may limit future therapeutic options when
needed (“Panel on Treatment” 2011).

Figure 5. Timeline of MTCT and different ARV interventions and their points of interaction (Adapted
from ICAP 2010).

Antiretroviral medications given at any point along the timeline seen in Figure 5, can
significantly decrease the risk of MTCT. In addition, ARVs given to the mother for their own
health can result in maternal mortality, so ARVs should be given to the mother for her own
survival. The timeline for MTCT in Figure 5 shows the different ARV interventions and their
point of interaction. Single-dose nevirapine (sd-NVP), a NNRTI, is the most commonly used
ARV prophylaxis. A single-dose is given to the laboring woman and her newborn infant.
Sd-NVP interrupts transmission during labor and delivery and early postpartum period. If
an additional short course of the NRTI azidothymidine (AZT, also known as zidovudine) is
taken during late pregnancy through delivery along with sd-NVP, protection extends
through late pregnancy. If a pregnant woman is treated for her own health, a maternal
combination therapy or maternal ARV prophylaxis has the ability to protect both her and
presumably her baby throughout the breastfeeding period. There has also been a shown
14

efficacy for protection during the postpartum period in breastfeeding infants who receive
daily NVP (Figure 5, ICAP 2010).
377 ARV-naïve infants 6-12 weeks of age

Immediate ARV therapy
(n = 125)

Deferred ARV therapy
(n = 252)

Primary outcome:
time to disease progression or death
Figure 6. Summary of the CHER study design (Adapted from Violari et al. 1994).

In the Children with HIV Early Antiretroviral Therapy (CHER) study, recent results
definitively determined there is an advantage to starting children on treatment before to
development of disease manifestations. In this landmark study, 377 infants six to twelve
weeks of age who were not immune suppressed or symptomatic were randomized to start
immediate treatment or deferred to ART when they met clinical criteria with a primary
outcome of time to disease progression or death (Figure 6). It was concluded that an early
HIV diagnosis and early ARV therapy during the first months of life reduced early infant
mortality by 76% and HIV progression by 75% (Figure 7, Violari et al. 2008).

Figure 7. Early treatment reduces the risk of death (Violari et al. 2008).
15

ANTIRETROVIRAL REGIMENS IN LOWER RESOURCE SETTINGS
Although antiretroviral regimens have been proven effective in the PMTCT, their
scale up has not been effective in lower resource settings. Current statistics provided by
United Nations Children’s Fund (UNICEF) reveal the low uptake of HIV testing and ART for
PMTCT in lower and middle resource settings. In their Fourth Stocktaking Report based on
2008 data, an estimated 21% of pregnant women living in lower resource countries
received an HIV test. Yet, only 45% of those who tested positive received some form of ARV
therapy or prophylaxis, and only 32% of exposed babies received some form of ARV
prophylaxis (UNICEF 2009, Figure 8). And if an ARV is received, it is most commonly a
single-dose of nevirapine, which will now be discussed.

Figure 8. Low uptake of HIV testing and ARV prophylaxis in lower resource countries, 2004-2008
(Adapted from UNICEF 2009).

16

NEVIRAPINE
Nevirapine (NVP), also marketed under the trade name Viramune, is a NNRTI
produced by the U.S. manufacturer Boehringer Ingelheim Pharmaceuticals Inc. NVP was
first approved by the U.S. Food and Drug Administration (FDA) in 1996 for use in
combination therapy and in 1998 for pediatric use (Menéndez-Arias et al. 2011). Approval
for combination therapy was based on a 1996 study done by D’Aquila and colleagues that
showed that adding NVP to two NRTIs, zidovudine and didanosine, was more effective in
increasing CD4+ counts and decreasing HIV viral load than zidovudine and didanosine alone
(D’Aquila et al. 1996). NVP is currently the only NNRTI drug with pediatric drug formulation
and neonatal dosing (“Panel on Treatment” 2011).
Structure. The chemical name of nevirapine is 11-cyclopropyl-5,11-dihydro-4methyl-6H-dipyrido[3,2-b:2',3'-e][l,4]diazepin-6-1 and the molecular formula is C15H14N4O.
Its chemical structure can be seen in Figure 9 (Campiani et al. 2002).

Figure 9. Chemical structure of nevirapine (Adapted from Menéndez-Arias et al. 2011).

Mode of action. As a NNRTI, nevirapine is a potent noncompetitive inhibitor of the
reverse transcriptase enzyme, preventing HIV’s viral RNA from being transcribed into DNA.
NVP does not bind at the enzyme’s active site like NRTIs, but allosterically at the
hydrophobic NNRTI pocket, a site away from the active site (Patel and Benfield 1996). NVP
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selectively inhibits HIV-1, but not HIV Type 2 (HIV-2) since the NNRTI pocket on HIV-2’s
reverse transcriptase enzyme has a different structure and has a higher than 8,000 fold
selectivity for infected than uninfected cells (Ren et al. 2002).
Dosage. Nevirapine comes in a tablet and a liquid oral suspension. It has been found
that higher concentrations of NVP (2.5-10mg/L) work best and can completely suppress
viral replication in cell cultures and protect uninfected cells (Patel and Benfield 1996).
Use in combination therapy. Addition of nevirapine to existing ART therapy produces
a more rapid and sustained immunological and virological response. Nevirapine shows a
higher synergistic inhibitory activity in combination with NRTIs. Due to the same molecular
target, NNRTIs and NRTIs complement each other in interfering with viral replication even
though they have different mechanisms of actions (Campiani et al. 2002). This was seen in
the D’Aquila et al. study that NVP’s FDA approval was based on.
So, if nevirapine works best in combination with NNRTIs, why do lower resource
countries rely on a single-dose of NVP to prevent mother-to-child transmission?

NEVIRAPINE: WHY SINGLE-DOSE?
HIVNET 012 trial. The simplest of all PMTCT drug regimens was tested in the HIV
Network for Prevention Trials (HIVNET) 012 study, which took place in Uganda between
1997 and 1999. This randomized clinical trial evaluated a simple ARV drug regimen to
prevent the transmission of HIV-1 from an infected mother to her child in a breastfeeding
population.
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HIV+ pregnant women naïve to ARVs

Single-dose nevirapine
Mother: 200mg dose
Infant: 2mg/kg within 72hrs

Zidovudine
Mother: 600mg dose + 300mg every 3 hrs
of delivery
Infant: 4mg/kg twice daily for 1 week

Transmission rate:
13.1%

Transmission rate:
25.1%

Figure 10. Summary of the HIVNET 012 trial design and its results (Adapted from Guay et al. 1999).

As seen in Figure 10, the experimental drug regimen consisted of a single oral dose
of 200mg nevirapine (sd-NVP) given at the onset of labor to HIV-infected pregnant women
along with a single-dose of nevirapine (2mg/kg) given to the baby within 72 hours of life.
The comparison group was given a zidovudine (ZDV) regimen consisting of a maternal oral
dose of 600mg along with 300mg every three hours of labor, in addition to a 4mg/kg ZDV
dose twice daily for the baby’s first week of life. ZDV was previously shown effective in
Conner et al.’s 1994 study. The HIVNET 012 study showed that the NVP regimen reduced
MTCT risk by 47% at 14 to 16 weeks compared to the ZDV regimen. At that age, the overall
transmission rate observed was 13.1% for the NVP group versus 25.1% for the ZDV group.
The transmission rate for the ZDV group was similar to those observed in the placebo
groups of other randomized clinical trials conducted in breastfeeding populations (Guay et
al. 1999).
With its findings that a single-dose of NVP given to the mother at the onset of labor
and to the baby after delivery can halve the rate of HIV transmission, the HIVNET 012 study
jumpstarted the implementation of sd-NVP regimens in low resource settings with high HIV
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prevalence. Coupled with rapid testing, women attending antenatal clinics could now be
counseled, tested, and given a single pill that could save the life of their child.
An open access program by Boehringer Ingelheim Pharmaceuticals Inc., the U.S.
manufacturer of NVP, and their local partners quickly facilitated the rapid expansion of
PMTCT programs using sd-NVP throughout the world (Abrams 2010).

IS SINGLE-DOSE NEVIRAPINE IDEAL?
Without a doubt, the HIVNET 012 study had and still has major implications for the
control of HIV transmission in many developing countries and has led to critical decisions in
the international health care community. The ease of administration and low cost of sdNVP makes it ideal for monotherapy for prophylaxis of perinatal transmission, especially in
settings where there are less resources and not enough antenatal care (Abrams 2010).
A study done by Marseille and colleagues in 1999 proposed the universal
administration of sd-NVP to all pregnant women at the time of labor and delivery and to
their newborns in settings with high HIV prevalence, regardless of HIV status (Marseille et
al. 1999). This proposal was based on the cost effectiveness (about $2/dose) and simplicity
of sd-NVP along with taking into account the technological difficulties of administering HIV
testing in pregnant women in these countries, the lack of prenatal care, and the relative
safety of sd-NVP for mothers and infants (Peters et al. 1999).
This proposal, however, has led to opposition from those who question the risk of
drug resistance caused by repeated exposure to nevirapine (during repeated pregnancies)
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and who point out that $4 is close to the annual health care expenditure per capita in some
African countries that are severely afflicted by HIV infection and AIDS.

PREGNANCY AND ANTIRETROVIRAL DRUG RESISTANCE
The development of ARV drug resistance is one of the major factors leading to
therapeutic failure in HIV-infected individuals. In pregnant mothers, there are specific
concerns that differ from the nonpregnant population. A pre-existing drug resistance to a
drug used in an ARV regimen can diminish the regimen’s efficacy for PMTCT. If a mother
develops resistance to drugs used during pregnancy to stop MTCT, her future options may
be limited. In addition, infant treatment options may also become limited if the mother
develops a resistant virus that is then transmitted to her fetus (“Panel on Treatment” 2011).
Several factors unique to pregnancy may increase the risk of developing resistance.
If drugs with significantly different half-lifes such as the combination of NVP and two NRTIs
are included in the regimen and the mother discontinues ARV therapy after delivery, there
is an increased chance of NNRTI resistance due to the persistent subtherapeutric drug
levels.

Nausea and vomiting associated with early pregnancy may also compromise

adherence and increase the risk of resistance (Lockman et al. 2007).

ANTIRETROVIRAL RESISTANCE FOLLOWING SHORT-COURSE PROPHYLAXIS
Viral resistance may emerge during ARV treatment and occurs frequently with
single-drug regimens and even more frequently with single-dose regimens. Viral resistance
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is a potential problem for women after short-term exposure to ARV drugs to prevent MTCT
and for infants who become infected despite ARV prophylaxis.
Even before ARV drugs are administered, HIV that contains mutations associated
with viral drug resistance is present at low levels not detectable using standard resistance
assays. Pre-existing resistant viral populations may be selected for or new mutations may
develop with any ARV drug or drug regimen that does not fully suppress viral replication.
Most studies have also reported that a high maternal plasma viral load or a low CD4+ count
are associated with an increased risk of resistance to any ARV drug. NNRTIs such as NVP are
drugs for which a single mutation leads to high-level resistance, whereas most NRTI drugs
require multiple sequential mutations to confer resistance (Mofenson et al. 2002).

OVERVIEW OF ANTIRETROVIRAL RESISTANCE EMERGING FROM SINGLE-DOSE
NEVIRAPINE
Development of resistance associated with short-term use of ARV drugs for PMTCT
is most common with sd-NVP. Over the last decade there has been a great deal of work
looking at the implications of NVP resistance mutations in mothers children who fail sd-NVP
PMTCT prophylaxis. Arrivé and colleagues published a meta-analysis of summarized data
looking at prevalence of NVP resistance mutations in the plasma of the mothers and infants
at four to eight weeks postpartum after sd-NVP use for PMTCT. The pooled estimates of
NVP resistance prevalence were found to be 35.7% in the mothers and 52.6% in the
children following sd-NVP (Figure 8). However, the administration of postpartum ARVs to
the mother can significantly reduce the frequency of detection of NVP-resistant strains. As
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seen in Figure 11, the prevalence of NVP resistance can be significantly reduced to 4.5% in
the mother and 16.5% in the child by adding short-course postpartum ARV therapy to
standard sd-NVP (Arrivé et al. 2007). It is important to remember that NVP resistance is
also associated with resistance to other NNRTIs due to the location of mutations on the
reverse transcriptase gene.

Figure 11. Plot of multiple studies grouped according to whether mothers and children received only
sd-NVP or sd-NVP + additional ARVs at 4-8 weeks postpartum (Arrivé et al. 2007).

Resistance to NVP develops rapidly if viral replication is not completely suppressed.
Because of NVP’s long half-life, the drug can be detected in plasma up to three weeks after
administration of a single-dose during labor and delivery (Cressey et al. 2005). This long
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half-life creates a long period of persistent subtherapeutic drug levels that cause a
predisposition to the development of resistant strains of HIV (Arrivé et al. 2007). Viral
strains resistant to NVP were detected at six weeks postpartum in 19% of ARV-naïve women
of the HIVNET 012 trial and in 15% of women on additional ARV therapy who received sdNVP during labor (Cunningham et al. 2002, Eshleman et al. 2001). The use of sd-NVP is
likely to result in HIV viral resistance which could lead to resistance of subsequent ARV
treatment combinations.

COMMON MUTATIONS FOLLOWING NEVIRAPINE TREATMENT
Amino acid, wild-type
Amino acid position
Amino acid, substitution
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Amino acid abbreviations: A, alanine; C, cysteine; G, glycine; H, histidine; I, isoleucine;
K, lysine; L, leucine; M, methionine; N, asparagine; V, valine; Y, tyrosine
Figure 12. Nevirapine associated mutations on the reverse transcriptase gene (Adapted from
International AIDS Society-USA 2006).

With nevirapine’s low genetic barrier for resistance, single-nucleotide changes in the
viral genome can cause high-level resistance to NNRTIs. The most prominent mutations
found after exposure to NVP treatment are the Y181C mutation and the K103N mutation,
correlating with amino acid changes in the hydrophobic pocket where NVP usually binds
(Figure 12). As stated previously, NNRTIs exert their antiviral effect against HIV by binding
to reverse transcriptase in a hydrophobic pocket located next to the active site of the
enzyme that blocks the process of DNA polymerzation, causing a conformational change in
this enzyme (Patel and Benfield 1996). The region of the hydrophobic pocket that NNRTIs
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bind predominantly involves amino acid codons 98-108 and 179-190. Since all NNRTIs bind
within the same pocket, a mutation observed with one NNRTI is usually observed with all
NNRTIs. Therefore, viral strains which are NVP resistant are also usually resistant to other
NNRTIs (Conway et al. 2001, Deeks 2006). Resistance to NNRTIs occurs as a result of
mutations that inhibit effective binding of the NNRTI, allowing DNA polymerization to
proceed in an unrestricted manner (Deeks 2006).
Furthermore, the predominant NVP resistance mutations appear at different time
points. In mothers, the Y181C mutation is predominant one week postpartum and the
K103N is predominant six to eight weeks postpartum. However, most infants with NVP
resistance were noted to be infected at birth, suggesting that the resistance mutations were
not being passed on from the mother, but instead when their actively replicating virus was
exposed to NVP (WHO 2010). Therefore, the transmission of resistant viral strains to infants
is not associated with an increased risk of MTCT.

SAFETY AND EFFICACY OF NEVIRAPINE PROPHYLAXIS FOR REDUCING HIV
DURING BREASTFEEDING
HIV transmission during breastfeeding has also reduced the overall effectiveness of
efforts to prevent MTCT.

Multiple studies have found multiclass drug resistance in

breastfeeding infants who became infected despite NVP prophylaxis. The overall risk of HIV
transmission through breastfeeding is around 35-40% during the first two years of life, with
the greatest risk by the first six to fourteen weeks of life, a time in which about 60-70% of
breast milk transmission occurs (ICAP 2010). Despite this risk, WHO recommends that HIV25

infected mothers living in lower resource countries exclusively breastfeed for at least six
months to improve infant survival (WHO 2010).
Resistance mutations have been found in maternal plasma and breast milk after sdNVP exposure. In a study of twenty women from Zimbabwe, Lee and colleagues looked at
paired specimens of plasma and breast milk. They found that 50% of the plasma samples
and 67% of the breast milk samples had detectable NNRTI mutations, predominantly the
K103N mutation (Lee et al. 2005). This observation of drug-resistance in sd-NVP exposed
women who breastfeed created much concern and led to trials investigating the use of daily
NVP to preserve safe breastfeeding among HIV infected women.
To allow for breastfeeding, yet reduce transmission, NVP dosages were extended for
up to six weeks of age in the “Six Week Extended-dose NVP” (SWEN) trial. The SWEN trial
compared postnatal infection in breastfeeding infants in Uganda, Ethiopia, and India who
received sd-NVP or six weeks of daily NVP. In infants uninfected at birth, MTCT at six weeks
was 5.3% in the sd-NVP arm versus 2.5% in the extended NVP arm. At six months, MTCT
was 9.0% in the sd-NVP arm versus 6.9% in the extended NVP arm (Moorthy et al. 2009).
Extended NVP allows for daily NVP prophylaxis for infants breastfeeding and lowers the rate
of HIV infection in comparison to sd-NVP.
Although the use of the SWEN regimen looks promising at preventing breast milk
HIV transmission, a study completed by Moorthy and colleagues on the Indian arm of the
SWEN trial showed that the SWEN regimen carries a high likelihood of NVP resistance if the
infant becomes infected within the first six weeks of life. As demonstrated in Figure 13, of
the infants diagnosed with HIV by six weeks of age, the SWEN-exposed infants had a
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significantly higher prevalence of NVP resistance at 92% than those who received sd-NVP, of
which only 38% developed NVP resistance when detected by standard population
sequencing. After six weeks of age, the prevalence of NVP resistance did not differ among
SWEN or sd-NVP exposed infants who became infected during breastfeeding (Figure 13,
Moorthy et al. 2009).

As with sd-NVP, the value of preventing HIV infection in a large

number of infants should be considered alongside the high risk of resistance associated with
extended NVP prophylaxis.

Figure 13. SWEN and sd-NVP exposed HIV+ infants diagnosed within the first six weeks of life or
after (Adapted from Moorthy et al. 2009).

Similar findings to Moorthy et al. were found by Church and colleagues when they
evaluated NVP resistance in the Ugandan SWEN cohort.

At six weeks, 84% of the

breastfeeding infants had NVP resistance in comparison to 50% who were only given sdNVP (Figure 14A). This is a 1.7 fold greater risk of resistance in SWEN group compared with
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sd-NVP when tested at 6 weeks of age. When a small group of these children were retested
a six months, 100% of 7 children in the SWEN group continued to have detectable NVP
resistance whereas only 1 of the 6 children, or 17%, in the sd-NVP group had detectable
resistance (Figure 14B, Church et al. 2008). These findings suggest that resistance is greater
in children with longer duration of exposure.

Figure 14. Nevirapine resistance results from SWEN and sd-NVP exposed infants. A, percentage of
infants with NVP resistance within first six weeks of life. B, percentage of infants who had
NVP resistance mutations at six weeks that were retested at six months (Adapted from
Church et al. 2008).

Resistance in breastfeeding HIV-infected infants of mothers on ART has also been
demonstrated by the Kisumu breastfeeding study (KiBS) completed in Kenya. In the KiBS,
pregnant women received either NVP or the protease inhibitor nelfinavir (NFV) along with
the nucleoside reverse transcriptase inhibitor combivir (AZT+3CT) from 34 weeks gestation
through 6 months postpartum. As seen in Figure 15, by six months of age, 24 infants were
HIV infected. Of the 24 infants, 9 were born to mothers on the NFV regimen and 15 were
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born to mothers on the NVP regimen. Resistance was detected among 9/9 (100%) of the
NFV exposed infants and in 7/15 (47%) of the NVP exposed infants (Zeh et al. 2011)
522 HIV+ pregnant women naïve to ARVs

310 mothers on NVP+AZT+3TC

212 mothers on NFV+AZT+3TC

HIV+ infants at 6 months: 4.8%
n = 15

HIV+ infants at 6 months: 4.2%
n=9

7 of 15 infants (47%) developed drug
resistance to maternal regimen

All 9 infants (100%) developed drug
resistance to maternal regimen

Figure 15. Summary of the KiBS study design and its results (Adapted from Zeh et al. 2011).

Mirochnick and colleagues decided to evaluate the serum concentrations of NVP
and 3TC of the uninfected infants of mothers on antiretroviral therapy in the KiBS. The
median concentrations in breastmilk of NVP and 3TC were 1,214ng/mL and 4,546ng/mL in
comparison to zidovudine’s 14ng/mL (Mirochnick et al. 2009). These biologically significant
concentrations of both NVP and 3TC in the infants demonstrate that NVP and 3TC can be
transferred in breast milk.

NEVIRAPINE-ASSOCIATED RESISTANCE MUTATIONS: IMPACT ON TREATMENT
It is now well established that sd-NVP use and NVP use in general for PMTCT can
cause viral mutations associated with NNRTI resistance. Infants who fail prophylaxis and
acquire infection despite NVP exposure tend to develop resistance. So what does this all
mean for the child with HIV infection presenting for treatment? The small numbers of
29

children infected in previous perinatal studies make it hard to determine especially when
most have been studied only six to eight weeks after exposure.
In the Nevirapine Resistance Study (NEVEREST), sd-NVP exposed children who were
eligible for ART were started on a combination of LPV/r+AZT+3TC therapy. Yet prior to
initiation of treatment, resistance testing was done for 257 symptomatic children between
the ages of six months and two years. Overall, 27% of the children had detectable NNRTI
major mutations using standard population sequencing. The Y181C mutation was found in
21% of the children and the K103N mutation was found in 5% of the children. Using allele
specific PCR testing for low level frequencies, an additional 13% of Y181C mutations and 9%
K103N mutations were detected. As seen in Figure 16, young children are at a much higher
risk for any NNRTI mutation in comparison to older children (Hunt et al. 2009). This
suggesting a fading of resistance over time, which may allows for ARV treatment
subsequent to sd-NVP exposure.

Figure 16. NNRTI resistance mutations at ART initiation in HIV+ children with prior exposure to sdNVP (Adapted from Hunt et al. 2009).
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HIV DRUG RESISTANCE AT ANTIRETROVIRAL TREATMENT INITIATION
SUBSEQUENT TO SINGLE-DOSE NEVIRAPINE EXPOSURE
The first published study looking at treatment failure in children previously exposed
to sd-NVP was presented by Lockman and colleagues in 2007. They studied the response to
NVP-based ARV treatment among thirty mothers and children who were previously part of
a trial that involved the administration of either a placebo or sd-NVP for the prevention of
MTCT. The results were quite dismal. As seen in Figure 17, there were significantly higher
rates of virologic failure among both the mothers and children who previously received sdNVP in comparison to those previously in the placebo group after NVP-based ARV initiation.
By 24 weeks, 77% of the children with previous sd-NVP exposure met viral failure with more
than 400copies/mL (Lockman et al. 2007)

Figure 17. Time to virologic failure in infants previously exposed to sd-NVP (Lockman et al. 2007).

Subsequent ARV treatment after sd-NVP exposure was also studied in the
International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) P1060 trial that
was recently been completed by Palumbo and colleagues. This study was designed to
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compare NVP versus LPV/r containing regimens given to ART-naïve children six months to
three years of age who had prior exposure to sd-NVP.
288 ARV-naïve infants 6 months to 3 years of age
with prior sd-NVP exposure

NVP+AZT/3TC

LPV/r+AZT/3TC

Primary outcome:
time to disease progression or death
Figure 18. Summary of the P1060 study design (Adapted from Palumbo et al. 2010).

As seen in Figure 18, the children were randomized to NVP+AZT/3TC or to
LPV/r+AZT/3TC arms and the primary end point was virologic failure or discontinuation of
treatment by week 24. The Data and Safety Monitoring Board (DSMB) recommended
closure of this study early due to its early findings. More children in the NVP arm (39.6%)
reached a primary viral end point in comparison to the LPV/r arm (21.7%) by 24 weeks. This
difference was most distinct in children under the age of one who were put on therapy,
with 45.3% in the NVP arm meeting failure compared to 23.3% in the LPV/r arm (Figure 19).
Baseline resistance to NVP was also detected at the initiation of treatment in 12% of the
children studied and was predictive of treatment failure. For the children in the NVP with
detectable resistance prior to therapy, 83% failed in comparison to only 18% in the LVP/r
arm with existing resistance (Palumbo et al. 2010). Since NVP is used widely for the
prevention of MTCT in lower resource settings, alternative strategies are urgently needed.
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Figure 19. Time to primary end point of virologic failure or discontinuation of treatment greater in
NVP in comparison to LVP/r arm in children under 12 months of age (Palumbo et al.
2010).

Palumbo et al.’s trial along with the NEVEREST study both showed that there is no
association between NNRTI mutations and protease inhibitor therapy (Palumbo et al. 2010,
Hunt et al. 2011). New WHO pediatric treatment guidelines now recommend the use of a
boosted protease inhibitor such as LPV for therapy in all NVP-exposed children under two
years of age (WHO 2010).

2010 WORLD HEALTH GUIDELINES FOR THE PREVENTION OF MOTHER-TOCHILD TRANSMISSION
The new 2010 WHO guidelines for PMTCT are based on two key approaches: lifelong
ART and ARV prophylaxis. Lifelong ART is for HIV+ women in need of treatment for their
own health, which is also effective in reducing MTCT. ARV prophylaxis prevents MTCT
during pregnancy, labor and delivery, and breastfeeding for HIV+ women not in need of
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treatment for their own health.

These revised guidelines are the first to include

recommendations on ARV prophylaxis during breastfeeding where breastfeeding is the
most appropriate choice (WHO 2010). This allows PMTCT interventions to continue into the
postpartum period.
Figures 20 and 21, summarize the new guidelines for both HIV+ pregnant women
and their infants. As shown in Figure 20, there is now a focus on maternal therapeutic ARV
for women with CD4+ counts less than 350cells/μL. For healthier women with CD4+ counts
greater than 350cells/μL, there are two comprehensive options for prophylaxis: A) AZT+ sdNVP during pregnancy and daily infant NVP during the post natal period or B) maternal ARV
prophylaxis during pregnancy and infancy (WHO 2010).
Mother: HIV+ during pregnancy will receive ARVs

CD4 count < 350 cells/µL

CD4 count > 350 cells/µL

Mother takes ARVS for her own health

Mother takes ARVs for her infant’s health

 Recommended course of triple ARVs to
be started ASAP and taken indefinitely

Option A (Maternal AZT)
 AZT from 14th week
 Sd-NVP in labor*
 AZT + 3TC in labor and delivery + 1 week
post-partum*
* Can be omitted if mother receives > 4
weeks of AZT during pregnancy

Option B (Maternal triple ARV
prophylaxis)
 triple ARVs from 14th week of
pregnancy until 1 week after
breastfeeding has finished

Figure 20. Summary of 2010 PMTCT WHO guidelines for HIV+ mothers in lower-resource countries
(Adapted from WHO 2010).

Figure 21 illustrates the new guidelines for infants born to HIV+ mothers. All infants
should now receive a course of medication which is linked to the drug regimen their mother
is taking. If the mother is taking ARVs for her own health, the infant should receive daily
NVP for six weeks. If the mother is only taking ARVs for her infant, then the infant should
receive daily NVP until one week after breastfeeding is ended. It is recommended that the
child breastfeed for the first six months if there is no other safe option. Afterwards, the
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mother can supplement breast milk or complementary feed. If the infant is not breastfed,
they should receive daily NVP or AZT for six weeks (WHO 2010).
Infant: status is unknown or negative. Receives daily NVP or AZT

Not breastfeeding
(alternative feeding)
 Infant should have daily NVP or AZT for
6 weeks

Breastfeeding
Exclusively breastfeed for 6 months then complementary feed and continue
breastfeeding for the first 12 months of life. Gradually wean.
Option B (Maternal triple ARV
Option A (Maternal AZT)
prophylaxis)
 If the mother is taking AZT for the infant,
• If the mother is taking ARVs for
then the infant should have daily NVP
her health, then the infant should
until 1 week after breastfeeding has
have daily AZT or NVP for 6 weeks
finished.

Figure 21. Summary of 2010 PMTCT WHO guidelines for infants born to HIV+ mothers in lowerresource countries (Adapted from WHO 2010).

With their recommendation of combination therapy instead of sd-NVP, the new
PMTCT WHO guidelines have the potential of bringing transmission rates in lower resource
settings to rival the one to two percent transmission rates in higher resource settings. In
2010, Kuhn and colleagues reviewed the potential impact of the new WHO criteria for
PMTCT using data from 1,025 HIV-inftected women and infants from Zambia. The new
criteria of using a CD4+ count below 350cells/μL required initiating therapy in 68% of
pregnant women and if fully effective has the possibility of preventing 92% of maternal
deaths and 88% of infant infections caused by MTCT (Kuhn et al. 2010).
The problem of pediatric HIV seems so simple to solve. Children need to be
identified early on and started on appropriate treatment as seen in the new WHO
guidelines. Yet, what about all the children previously exposed to sd-NVP?
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LOPINAVAR/RITONAVIR: ANOTHER OPTION FOR CHILDREN PREVIOUSLY
EXPOSED TO NEVIRAPINE?
A number of other strategies have looked at whether or not there are other options
for children who have been previously exposed to NVP and if there is other options besides
NVP for life-long treatment in children. However, as seen in Table 2, there are very few ARV
medications currently approved for children in low resource settings (Adams 2010).
Table 2. ARV medications approved and available for children in lower resource settings (Adapted
from Abrams 2010).

NNRTI

NRTI

Integrase
Inhibitor

Protease
Inhibitor

ABC 2
-----------LPV/r 2
DDI
D4T
3TC
ZDV
1
Only for children >3 years
2
Not widely available in a majority lower resource countries
3
Limited availability in some lower resource countries
NVP
EFV 1

CCR5 receptor
antagonist

Fixed dose
Combination

-------------

NVP+3TC+D4T

The global ART scale-up has been anchored on the usage of NNRTI-based regimens
due to their low cost including generic and pediatric formulations. Protease inhibitor-based
ART is reserved for second-line therapy and has a limited availability and relatively high
cost. Lopinavar/ritonavir (LPV/r) is currently the only protease inhibitor option available for
young children since dosing and/or formulations of other PIs are not available or approved.
LPV/r was recently used in another arm of the NEVEREST study that looked at sdNVP exposed children with NNRTI resistance. Their findings indicate that an induction
period with full viral suppression after the administration of LPV/r+3TC+d4T (d4T:
stavudine) allows for the safe reintroduction of NNRTIs and the ability to stop LPV/r use and
reuse it as a second line therapy.
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323 sd-NVP exposed children
6 weeks to 24 months of age

Start LPV/r+3TC+d4T

195 infants eligible for randomization

Stay on LPV/r:
99 infants

Stay on LPV/r:
96 infants

Primary outcome:
52 weeks or viral suppression (<50copies/mL)
Figure 22. Summary of the NEVEREST NVP resistance study design (Adapted from Cooavadia et al.
2009).

As shown in the diagram of the study in Figure 22, 323 sd-NVP exposed infants
started LPV/r+3TC+d4T treatment and 195 reached viral suppression. The 195 were then
randomized to LPV/r or switched to NVP. The primary endpoint was a sustained viral
suppression of less than 50copies/mL or 52 weeks. The children who switched to NVP were
more likely to fully suppress to less than 50copies/mL. However, upon looking at Figure 23
and the more clinically meaningfully sustained viral suppression of less than 1,000copies/mL
at 52 weeks, fewer children in the NVP switch group (84.9%) than in the control group
(96.8%) were able to maintain suppression (Coovadia et al. 2009). This study illustrates that
sd-NVP associated NNRTI mutations prior to the initiation of therapy are directly related to
the risk of losing suppression when the infant is switched back to NVP.
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Percentage (%) that sustained viral suppression of
less than 1,000copies/mL at 52 weeks

96.8

98.0
96.0
94.0
92.0
90.0
88.0

84.9

86.0
84.0
82.0
80.0
78.0

Switch to NVP

Stay on LPV/r

Figure 23. NEVEREST NVP resistance study: sustained viral suppression on children in the NVP switch
group in comparison to the control group at 52 weeks.

Although LPV/r seems is definitely an option for PMTCT, there are still many issues
that come along with it. Currently, only a liquid form of LPV/r is available for infants and is
poorly palatable. LPV/r also requires a cold chain, which is not ideal in transporting the ARV
to distant clinics in hot climates served by poorly developed transport networks (Barragan
et al. 2008). In addition, LPV/r cannot be used in many HIV+ children who are co-infected
with tuberculosis due to its interactions with rifampin, a widely used tuberculosis treatment
medication, which jeopardizes viral suppression (Abrams 2010).
So as recent studies support the replacement of sd-NVP with LPV/r, it is important to
note that the ARV rollout in most low resource countries has been saving children,
especially young children.
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POSITIVE EFFECTS OF ANTIRETROVIRAL THERAPY PROGRAMS IN LOW
RESOURCE SETTINGS
Although it seems like at times PMTCT strategies are failing, there are generally
favorable results of ART for children in low resource settings. Even with a modestly
functioning PMTCT program, benefits for survival of young children are becoming quickly
evident.

With more comprehensive treatment coverage, and more efficient PMTCT

including AZT in addition to sd-NVP, further significant reductions in early life mortality have
been achieved.

Figure 24. Children receiving ART have high weight-for-age Z scores and CD4+ percentages, Zambia
(Bolton-Moore et al. 2007).

A study done in Zambia demonstrates the excellence of PMTCT programs based on
simple regimens in children, especially in young children. In the study, care was provided by
clinicians such as nurses and clinical officers in primary health care settings. Children
received three-drug ART (AZT+3TC+NVP) if they tested positive for HIV antibodies and
showed signs of immunosuppression. In the study, surviving children less than 18 months
had high weight-for-age Z scores and high CD4+ counts (Figure 24, Bolton-Moore et al,
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2007). Improvement in weight was more pronounced in the younger children as compared
with the older children and the average child experienced more than a doubling of his or
her CD4+ cell percentage in the first year of ART. These both show that good clinical
outcomes can be obtained by treating children with ART at primary health care facilities
using nonphysician clinicians in lower resource settings such as sub-Saharan Africa.

Under 2
Post-neonatal
1-2 yrs old
Neonatal

Figure 25. Decline in early life mortality with PMTCT ART services in KwaZulu-Natal, South Africa
(Adapted from Ndirangua et al. 2010).

When regimens based on AZT plus sd-NVP for the mother and child are not
acceptable or feasible, ARV prophylaxis using solely sd-NVP remains a practical regimen.
Progress in implementing programs to prevent MTCT based on single-dose maternal and
infant NVP or other short course regimens should not be undermined. There has been a
large decline in early life mortality of children born to HIV+ mothers in KwaZulu-Natal, South
Africa from 2001 to 2006 with the implementation of PMTCT and ART programs based on
sd-NVP (Figure 25). Although crude mortality rates in the neonatal and early childhood ages
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remained relatively stable, there was a large decline in the postneonatal mortality rates and
the numbers of deaths in children under two years of age declined by 49% from 2000 to
2006. With the rollout of a PMTCT program in 2001, child mortality rates declined by 36%
folllowed by a futher 20% decline after an HIV treatment program based on sd-NVP was
established in 2004 (Ndirangua et al. 2010). These findings confirm that even with a
modestly functioning PMTCT and HIV treatment program, children are benefiting.

Figure 26. Increased use of more complex ARV regimens in ICAP-supported PMTCT programs 20072009 in eight different African countries (ICAP 2010).

The International Center for AIDS Care and Treatment Programs (ICAP) supports HIV
care and PMTCT programs in eight different African countries. Figure 26, shows the general
trend across all the African sites supported through ICAP over a two year period from 2007
to 2009. It is encouraging to see that there has been a general trend away from sd-NVP to
multi-drug regimens, primarily AZT+sd-NVP (ICAP 2010).
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With more comprehensive

treatment coverage, and more effective PMTCT including combination therapy with AZT in
addition to sd-NVP, futher significant reductions in child mortality is expected.
Although, progress is being made on the problem of pediatric HIV. The ultimate
solution lies in the prevention of mother-to-child transmission and in preventing HIV
infection in women.

In order for lower resource countries to achieve clinical and

immunological outcomes comparable to those seen in higher resource countries such as the
United States, the scaling-up of HIV treatment and PMTCT programs needs to be realized.

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION IS POSSIBLE
Recently in 2009, UNAIDS and partners have called for virtual elimination of HIV
transmission from mother-to-child by 2015. Virtual elimination includes the overarching
goal of keeping mothers alive, reducing the number of new child HIV infections by 90%
between 2009 and 2015, and reducing MTCT to less than 5%. To achieve this, the United
Nations recommends the use of their previously mentioned four-pronged approach: (1)
primary prevention of HIV infection of women of childbearing age (2) preventing
unintended pregnancies among HIV+ women (3) preventing MTCT (4) provided treatment
to HIV+ mothers and their families (UNAIDS 2010). In 2009, there were 347,000 new child
infections. A 90% reduction would require fewer than 34,700 new infections in 2015 (Mahy
et al. 2010). This is an ambitious aim, but also a realistic one that can be achieved with
significantly increased implementation of proven strategies. Many lower income countries
have already moved significantly towards achieving these goals by achieving at least 80%
coverage of services to prevent MTCT, with global coverage reaching 53% (UNAIDS 2010).
42

Projecting into the future, if current programs were improved so that by 2015 90%
of HIV+ pregnant women were provided with ART or effective ARV prophylaxis during
pregnancy and throughout breastfeeding as currently recommended by WHO,
approximately 1,041,000 new child infections would be averted (Figure 27). This is a 60%
reduction in the annual number of new child infections, which is a major step forward but

Children with HIV

still well below the goal of 90% (Mahy et al. 2010).

Year

Figure 27. New HIV infections in children ages 0-14 through MTCT for different scenarios 2009-2015
(Mahy et al. 2010).

Even if there is not exactly a 90% reduction of new child HIV infections by 2015, it is
important to note that it is still feasible to one day stop MTCT of HIV. If HIV+ pregnant
women and their children have timely access to quality ARVs—for their own health or as
prophylaxis to stop HIV transmission during pregnancy, delivery, and breastfeeding—it is
possible to stop new HIV infections among children and keep their mothers alive. This is
where the importance of moving rapidly to the new, more effective ARV interventions
recommended in the 2010 WHO guidelines comes into play. Using the new WHO guidelines
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for ARVs, MTCT can be virtually eliminated and together with a comprehensive approach to
reduce new infections in women and meet family planning needs, rapid progress can be
made towards virtual elimination.

CONCLUSIONS
Ultimately, a large number of mothers and children continue to receive sub-optimal
single-dose nevirapine as their main HIV prophylaxis. This must be phased out not only in
accordance with the 2010 WHO guidelines, but in order to reach the new target of virtual
elimination of mother-to-child transmission.
It is clear that the use of sd-NVP places both mother and child at risk for acquiring
NNRTI resistance mutations which creates challenges to achieving successful subsequent
treatment. NNRTI resistance in infants exposed to sd-NVP compromises the response to
subsequent NNRTI-based treatment and can jeopardize simpler first-line treatment,
necessitating the use of second-line regimens containing drugs that are costlier and more
difficult to administer. This is particularly worrisome in infants initiating lifelong therapy.
LPV/r-based ART is the preferred regimen for HIV-infected infants with prior NVP
exposure for PMTCT prophylaxis. However, there are multiple issues associated with LPV/r
and there are few options currently available for children who do not tolerate or fail firstline LPV/r-based ART.
On the other hand, a program to prevent MTCT that cannot deliver or ensure
adherence to a more complex prophylaxis regimen is less effective than a program that
implements the simpler sd-NVP regimen even though the more complex regimen may have
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shown greater efficacy in clinical trials. Although sd-NVP may not be the most optimal
regimen, it is important to realize that there are still more than a thousand new pediatric
infections occurring each day, primarily due to mother-to-child transmission. Sd-NVP will
always outweigh the high risk for death and disease progression associated with no
interventions.
In the end, alternative approaches and new ARVs are urgently needed to ensure safe
and successful lifelong ART for infants and children with HIV infection. For it is the scale-up
of more effective ARV interventions, together with a comprehensive approach to reduce
new infections in pregnant women and meet family planning needs, that creates rapid
progress towards virtual elimination of mother-to-child transmission of HIV.
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